Samsung Electronics becomes largest shareholder in Element Biosciences, expected to expand reach in digital health care
2026.06.10 16:56
Samsung Electronics has become the largest shareholder of the U.S. gene analysis equipment company Element Biosciences — a move that could strengthen its digital health care business and expand its presence in the precision medicine market.
Samsung Electronics said on Wednesday that it participated in Element Biosciences' Series E funding round, making an additional $175 million equity investment to become the largest shareholder. Samsung Electronics previously participated in the company's Series D funding round in 2024.
According to Samsung Electronics, it plans to remain a strategic investor and will not be involved in management control.
San Diego-based Element Biosciences is a next-generation DNA sequencing company founded in 2017. The company has grown rapidly and has improved genome analysis accuracy to 99.99 percent while significantly reducing sequencing costs.
DNA sequencing is used to read the genetic code of living organisms and analyze genetic traits and mutations. The technology is used to predict the likelihood of disease, develop personalized treatments and has also emerged as a key tool for early cancer detection and drug development.
Samsung Electronics is particularly interested in Element Biosciences' multiomics technology, which integrates and analyzes biological information such as DNA, RNA and proteins to identify the causes of diseases and track how they progress.
Traditionally, researchers had to analyze DNA, RNA and proteins separately with different equipment. But Element Biosciences developed technology — its Aviti24 system, introduced last year — that can simultaneously analyze DNA, RNA and proteins at the single-cell level while also tracking changes in cell morphology.
Industry observers expect Samsung Electronics to accelerate efforts to connect genomic analysis data to its mobile and wearable ecosystem.
Combining genetic information with data — surrounding sleep, exercise and heart rate — collected by the Galaxy Watch and Galaxy Ring could enable highly personalized health care services that analyze an individual's health and predict disease risk.
Integrating Samsung's AI technology and big-data processing capabilities with Element Biosciences' genomic analysis platform could also accelerate genomic data analysis and improve the accuracy of disease diagnosis.
Industry representatives are also watching whether DNA-based personalized health management and disease prediction services could eventually be expanded through Samsung Health.
“The combination of Samsung Electronics' expertise in AI, medical devices and digital health with Element Biosciences's innovative genomic analysis technology will create synergies for the future of personalized medicine,” said Roh Tae-moon, the head of Samsung Electronics' Device eXperience Division.
“We will continue investing across a broad range of fields, from precision medical devices to digital health,” he added.
저작권 보호를 위해 본문의 일부만 표시됩니다.
원문 보기 →댓글 (0)
첫 번째 댓글을 작성해보세요!
investing의 다른 소식
Samsung becomes largest shareholder in Element Biosciences with US$175 mln investment
0
모든 소식을 불러왔습니다